OmniComm to provide TrialMaster EDC technology to undisclosed CRO
These studies are the important first step in determining the safety and tolerability of new drugs. They test how drugs are absorbed into the body, and the amount
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Fibrocell’s clinical program for RDEB will utilize PCT’s manufacturing expertise and resources to implement the production process for transfer and clinical manufacturing of genetically-modified cell therapies. The manufacturing
Tekmira is also conducting a separate Phase I/II clinical trial evaluating TKM-PLK1 in patients with Gastrointestinal Neuroendocrine Tumors (GI-NET) or Adrenocortical Carcinoma (ACC). "Hepatocellular carcinoma is associated with